What smart money is saying about Adaptive Biotechnologies
ADPT
No fund has written a full thesis on Adaptive Biotechnologies in our archive, but 3 fund letters report a position in it — most recently Aristotle Focus Growth Equity in September 2025.
Get an email when a fund writes about it
3
Reported positions
0
Bought
0
Sold
3
Letters
Position history
Between Q2 2025 and Q3 2025, 3 fund letters reported a position in Adaptive Biotechnologies, with no move described.
| Quarter | Letters | Bought | Sold | Theses |
|---|---|---|---|---|
| Q3 2025 | 2 | 0 | 0 | 0 |
| Q2 2025 | 1 | 0 | 0 | 0 |
Fund activity · 3 positions
- September 2025
“Adaptive Biotechnologies Adaptive Biotechnologies contributed to performance in the third quarter as momentum continued in its minimal residual disease (MRD) testing business, anchored by its flagship clonoSEQ test for MRD in several hematological cancers.”
Adaptive Biotechnologies - September 2025
“Adaptive Biotechnologies Adaptive Biotechnologies contributed to performance in the third quarter as momentum continued in its minimal residual disease (MRD) testing business, anchored by its flagship clonoSEQ test for MRD in several hematological cancers.”
Adaptive Biotechnologies - June 2025
“Adaptive Biotechnologies Adaptive Biotechnologies contributed to relative performance in the second quarter following a better- than-expected first quarter earnings report, which showed solid across-the-board momentum in both clinical testing and biopharma testing volumes.”
Adaptive Biotechnologies
Read the letters behind these Adaptive Biotechnologies positions
Every quote above comes from a fund letter in our archive. Get unlimited access to the letters themselves — and to Warren AI, which reads all of them for you.
View plans→Share this ledger